



SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Tokyo, Japan and Mountain View, Calif. – January 6, 2021 - The SanBio Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) (TSE:4592) a scientific leader in regenerative medicine for neurological disorders, today announced that Keita Mori, Chief Executive Officer and Bijan Nejadnik, MD, Chief Medical Officer and Head of Research will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:50 a.m. Eastern Time (11:50 p.m. JST). The conference will be held January 11-14, 2021 in a virtual meeting format.

A link to the live and archived webcast may be accessed on [the J.P. Morgan website](#). An archive of the webcast will be available for thirty days. The presentation material will also be available on SanBio's website under the IR section after the session: [here](#).

About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company's proprietary regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and stroke. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at <https://sanbio.com/en>.

For more information, contact:

SanBio Co., Ltd.

Management Administration

info@sanbio.jp